The second study utilized a crossover design in evaluating 12 normotensive patients with only HFPEF. [22] Patients with a history of ischemic heart disease who had signs and symptoms of heart ...

A recent study found that tirzepatide, the active ingredient in Zepbound and Mounjaro, could reduce the risk of ...

In HFpEF, the heart can pump normally but its ... pressure (hypertension), obesity and diabetes. They typically have symptoms such as shortness of breath, fatigue and reduced ability to exercise.

Catheter ablation is associated with significant reductions in AF symptoms, AF-related hospitalization, and HF symptoms across HF subtypes.

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

After 19 weeks on daily oral HU6 treatment, people shed on average 2.9 kg (~6.3 lb) or 2.7% of their starting body weight relative to placebo, both significant changes supporting some efficacy of the ...

Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure ...

Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...

Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...